Cristiane dos Santos Dias
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cristiane dos Santos Dias has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Lilian Martins Oliveira Diniz
Departamento de Pediatria, Universidade Federal de Minas Gerais, Belo Horizonte 30130-110, MG, Brazil
5 shared publications - Ana Cristina Simoes-E-Silva
Department of Pediatrics, Unit of Pediatric Nephrology, Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil
4 shared publications - Bárbara Lopes Farace
Hospital Risoleta Tolentino Neves, Belo Horizonte, Brazil
4 shared publications - Carla Thais Cândida Alves da Silva
Hospital Santo Antônio, Curvelo, Brazil
4 shared publications - Daniella Reis Barbosa Martelli
Health Science/Primary Care Postgraduate Program, State University of Montes Claros (Unimontes), Montes Claros 39401-089, MG, Brazil
4 shared publications - Eduardo Araujo Oliveira
Federal University of Minas Gerais (UFMG), Brazil; University of California, U.S.A.
4 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (9) , 1984
Risk Factors of COVID-19 Severity and Related Death in Children in the Post-Pandemic Era
In the post-pandemic era, identifying children who are most susceptible to severe illness and COVID-19-related mortality is essential for guiding public health policies. This study examined the risk factors for COVID-19-related severe illness and mortality from 2023 to mid-2025. We conducted a population-based cohort study using nationwide Brazilian data from patients aged p < 0.001) and death (aOR = 2.1; 95% CI: 1.3–3.5; p < 0.001). In the post-pandemic era, younger age, comorbidities, sociodemographic disparities, and lack of vaccination were associated with an increased risk of severe illness and COVID-19-related death in the pediatric population.
- 8 September 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (9) , 1984
Open AccessRisk Factors of COVID-19 Severity and Related Death in Children in the Post-Pandemic Era
In the post-pandemic era, identifying children who are most susceptible to severe illness and COVID-19-related mortality is essential for guiding public health policies. This study examined the risk factors for COVID-19-related severe illness and mortality from 2023 to mid-2025. We conducted a population-based cohort study using nationwide Brazilian data from patients aged p < 0.001) and death (aOR = 2.1; 95% CI: 1.3–3.5; p < 0.001). In the post-pandemic era, younger age, comorbidities, sociodemographic disparities, and lack of vaccination were associated with an increased risk of severe illness and COVID-19-related death in the pediatric population.
- Open Access
- 26 May 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e84444
Large Language Model–Generated Patient Instructions for Prescriptions in Primary Health Care: Preclinical Algorithm Validation
Background: The application of generative artificial intelligence to simplify medication use instructions has the potential to enhance people’s health by improving treatment adherence. Objective: We evaluated the performance of large language models (LLMs) in generating medication usage instructions to complement prescriptions in primary health care. Methods: This randomized, blinded experimental preclinical study used prescription-inducing scenarios, assigned to 62 health care professionals, to validate instructions generated by LLMs during electronic prescriptions. The instructions were generated by ChatGPT-4.0 (OpenAI), Llama3.1-8B (Meta), and Llama3.1-8B-RAG (Meta) using retrieval-augmented generation based on patient information leaflets. Performance metrics assessed adequacy, completeness, clarity, language simplification, usefulness, and errors in the generated instructions, with scores to analyze overall and individual metrics. Results: The 3 models yielded high overall scores for producing qualified instructions (ChatGPT-4.0: median 88.4, IQR 22.8; Llama3.1-8B: median 66.5, IQR 50.9; Llama3.1-8B-RAG: median 79.9, IQR 34.4; Kruskal-Wallis test P=.003). Llama3.1-8B-RAG received evaluations with similar overall scores to ChatGPT-4.0 (post hoc test, P=.05) and similar to Llama3.1-8B (post hoc test, P=.44). ChatGPT-4.0 outperformed Llama3.1-8B (Bonferroni test, P<.001). Regarding specific domains, Llama3.1-8B-RAG received scores equivalent to those of ChatGPT-4.0 for adequacy (mean 6.24, SD 2.3 vs mean 6.82, SD 2.1; post hoc test, P=.54); completeness (mean 5.94, SD 2.2 vs 6.55, SD 1.9; post hoc test P=.38), clarity (mean 5.77, SD 2.4 vs mean 6.68, SD 1.9; post hoc test P=.09), and usefulness (mean 5.42, SD 2.4 vs mean 5.96, SD 2.2; post hoc test P=.63). ChatGPT-4.0 received higher scores in the language simplification criterion than Llama3.1-8B-RAG (mean 7.05, SD 1.5 vs mean 5.44, SD 2.6; post hoc test P<.001). Interrater variability in assigning scores ranged from 4.2% (n=3) to 85.8% (n=6) among primary health care professionals. Instructions leading to incorrect use of the medication had similar frequency among the models(ChatGPT-4.0: n=15, 22.7%; Llama3.1-8B: n=19, 22.8%; Llama3.1-8B-RAG: n=19, 22.8%; chi-square test P=.71). The frequencies of hallucination were similar (ChatGPT-4.0: n=7, 10.6%; Llama3.1-8B: n=9, 13.6%; Llama3.1-8B-RAG: n=6, 9.1%; chi-square test P=.67). Conclusions: The open-source LLM enhanced with external information presented similar performance to the closed-source model, except for ChatGPT4.0, which was superior in language simplification of messages. LLM generation demonstrated potential for instructing patients on medication use. Nonetheless, the introduction of this innovation into the electronic prescribing workflow demands prescriber validation for human oversight of the technology and requires a strategy for LLM performance governance. International Registered Report Identifier (IRRID): RR2-10.12688/verixiv.1359.1
- 26 May 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e84444
Open AccessLarge Language Model–Generated Patient Instructions for Prescriptions in Primary Health Care: Preclinical Algorithm Validation
Background: The application of generative artificial intelligence to simplify medication use instructions has the potential to enhance people’s health by improving treatment adherence. Objective: We evaluated the performance of large language models (LLMs) in generating medication usage instructions to complement prescriptions in primary health care. Methods: This randomized, blinded experimental preclinical study used prescription-inducing scenarios, assigned to 62 health care professionals, to validate instructions generated by LLMs during electronic prescriptions. The instructions were generated by ChatGPT-4.0 (OpenAI), Llama3.1-8B (Meta), and Llama3.1-8B-RAG (Meta) using retrieval-augmented generation based on patient information leaflets. Performance metrics assessed adequacy, completeness, clarity, language simplification, usefulness, and errors in the generated instructions, with scores to analyze overall and individual metrics. Results: The 3 models yielded high overall scores for producing qualified instructions (ChatGPT-4.0: median 88.4, IQR 22.8; Llama3.1-8B: median 66.5, IQR 50.9; Llama3.1-8B-RAG: median 79.9, IQR 34.4; Kruskal-Wallis test P=.003). Llama3.1-8B-RAG received evaluations with similar overall scores to ChatGPT-4.0 (post hoc test, P=.05) and similar to Llama3.1-8B (post hoc test, P=.44). ChatGPT-4.0 outperformed Llama3.1-8B (Bonferroni test, P<.001). Regarding specific domains, Llama3.1-8B-RAG received scores equivalent to those of ChatGPT-4.0 for adequacy (mean 6.24, SD 2.3 vs mean 6.82, SD 2.1; post hoc test, P=.54); completeness (mean 5.94, SD 2.2 vs 6.55, SD 1.9; post hoc test P=.38), clarity (mean 5.77, SD 2.4 vs mean 6.68, SD 1.9; post hoc test P=.09), and usefulness (mean 5.42, SD 2.4 vs mean 5.96, SD 2.2; post hoc test P=.63). ChatGPT-4.0 received higher scores in the language simplification criterion than Llama3.1-8B-RAG (mean 7.05, SD 1.5 vs mean 5.44, SD 2.6; post hoc test P<.001). Interrater variability in assigning scores ranged from 4.2% (n=3) to 85.8% (n=6) among primary health care professionals. Instructions leading to incorrect use of the medication had similar frequency among the models(ChatGPT-4.0: n=15, 22.7%; Llama3.1-8B: n=19, 22.8%; Llama3.1-8B-RAG: n=19, 22.8%; chi-square test P=.71). The frequencies of hallucination were similar (ChatGPT-4.0: n=7, 10.6%; Llama3.1-8B: n=9, 13.6%; Llama3.1-8B-RAG: n=6, 9.1%; chi-square test P=.67). Conclusions: The open-source LLM enhanced with external information presented similar performance to the closed-source model, except for ChatGPT4.0, which was superior in language simplification of messages. LLM generation demonstrated potential for instructing patients on medication use. Nonetheless, the introduction of this innovation into the electronic prescribing workflow demands prescriber validation for human oversight of the technology and requires a strategy for LLM performance governance. International Registered Report Identifier (IRRID): RR2-10.12688/verixiv.1359.1
- Open Access
- 14 April 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (4) , 883
Effectiveness of COVID-19 Vaccine Boosters in Children Across Pandemic and Endemic Periods
In the SARS-CoV-2 endemic phase, assessing the effectiveness of COVID-19 booster doses in children is essential for public health policy. This study evaluated the vaccine effectiveness (VE) of three doses (primary series plus booster) against severe outcomes, comparing the pandemic and endemic periods and children with and without comorbidities. We carried out a cohort study based on the population, utilizing comprehensive Brazilian data from individuals under 18 years of age with confirmed SARS-CoV-2 infection, spanning from February 2020 to June 2025. The primary exposure of interest was three or more doses of COVID-19 vaccines. The primary outcome of interest was COVID-19-related death. VE and the number needed to vaccinate (NNV) to prevent one death were estimated in a propensity score-matched cohort, with adjustments for confounders. Among 3,730,007 reported pediatric cases, 5472 (0.1%) died, 99% of whom did not receive a booster dose. During the pandemic, the VE against death was higher in children with comorbidities (92.7% [95% CI, 63.5–99.0]; NNV = 23 [19–30]) than in those without (68.2% [25.7–86.4]; NNV = 2000 [1111–9774]). During the endemic period, the VE against death remained high and was comparable between groups: 89.4% (29.8–98.7) and 75.8% (36.4–95.7) for children with and without comorbidities, respectively. Nevertheless, NNV levels were significantly lower in children with comorbidities, reflecting an increased risk at baseline. Although booster doses continue to offer substantial protection against fatal COVID-19 outcomes, the magnitude of this benefit is directly correlated with the baseline risk. Consequently, these findings support the implementation of risk-based prioritization strategies in public health decision-making for children.
- 14 April 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (4) , 883
Open AccessEffectiveness of COVID-19 Vaccine Boosters in Children Across Pandemic and Endemic Periods
In the SARS-CoV-2 endemic phase, assessing the effectiveness of COVID-19 booster doses in children is essential for public health policy. This study evaluated the vaccine effectiveness (VE) of three doses (primary series plus booster) against severe outcomes, comparing the pandemic and endemic periods and children with and without comorbidities. We carried out a cohort study based on the population, utilizing comprehensive Brazilian data from individuals under 18 years of age with confirmed SARS-CoV-2 infection, spanning from February 2020 to June 2025. The primary exposure of interest was three or more doses of COVID-19 vaccines. The primary outcome of interest was COVID-19-related death. VE and the number needed to vaccinate (NNV) to prevent one death were estimated in a propensity score-matched cohort, with adjustments for confounders. Among 3,730,007 reported pediatric cases, 5472 (0.1%) died, 99% of whom did not receive a booster dose. During the pandemic, the VE against death was higher in children with comorbidities (92.7% [95% CI, 63.5–99.0]; NNV = 23 [19–30]) than in those without (68.2% [25.7–86.4]; NNV = 2000 [1111–9774]). During the endemic period, the VE against death remained high and was comparable between groups: 89.4% (29.8–98.7) and 75.8% (36.4–95.7) for children with and without comorbidities, respectively. Nevertheless, NNV levels were significantly lower in children with comorbidities, reflecting an increased risk at baseline. Although booster doses continue to offer substantial protection against fatal COVID-19 outcomes, the magnitude of this benefit is directly correlated with the baseline risk. Consequently, these findings support the implementation of risk-based prioritization strategies in public health decision-making for children.
- Open Access
- 20 February 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (2) , 501
Effectiveness of COVID-19 Vaccines Against Hospitalization and Severe Disease in Children with Diabetes Mellitus During Pandemic and Post-Pandemic Eras
Pediatric patients with SARS-CoV-2 infection are at an increased risk of severe disease and adverse outcomes. Nevertheless, comprehensive data on COVID-19 vaccine effectiveness (VE) in children with diabetes during the post-pandemic period remain limited. This study assessed the VE against severe COVID-19 outcomes during both the pandemic and post-pandemic phases in children with and without diabetes mellitus (DM). A cohort study based on population data was carried out, including all patients under 18 years of age with symptomatic SARS-CoV-2 infection as registered in the Brazilian national surveillance systems from February 2020 to June 2025. The main outcomes were hospitalization due to COVID-19 and severe illness, which included admission to the intensive care unit (ICU), need for invasive ventilation, and death. Utilizing a propensity score-matched cohort, we estimated the VE and the number needed to vaccinate (NNV) for a booster dose against these outcomes by comparing vaccinated and unvaccinated individuals, employing conditional logistic regression adjusted for confounding variables. The cohort comprised 3,730,007 pediatric patients with COVID-19, of whom 7675 (0.2%) had DM. At baseline, children with DM exhibited a significantly higher prevalence of hospitalization (11.2% vs. 2.0%), severe COVID-19 (6.4% vs. 0.6%), and mortality (1.9% vs. 0.1%) than those without DM (all p < 0.001). During the pandemic period, the adjusted VE was consistently higher in children with DM. Against severe disease, the VE was 72.8% (95% CI: 12.3–93.2) in the DM cohort compared with 45.7% (28.1–59.0) in the non-DM cohort. This increased effectiveness corresponded to a more favorable NNV; the NNV to prevent one severe case was 24 (95% CI: 12–232) for children with DM versus 243 (168–440) for those without DM. In the post-pandemic period, the VE remained significantly higher in the DM cohort. Against severe disease, the VE was 76.2% (11.5–93.5) for children with DM and 52.9% (32.7–67.1) for those without. The NNV to prevent one severe case was consistently lower in the DM cohort (8 vs. 591). In conclusion, a complete vaccination regimen, including a booster dose, substantially mitigated severe COVID-19 outcomes in children with DM in the pandemic and post-pandemic periods.
- 20 February 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (2) , 501
Open AccessEffectiveness of COVID-19 Vaccines Against Hospitalization and Severe Disease in Children with Diabetes Mellitus During Pandemic and Post-Pandemic Eras
Pediatric patients with SARS-CoV-2 infection are at an increased risk of severe disease and adverse outcomes. Nevertheless, comprehensive data on COVID-19 vaccine effectiveness (VE) in children with diabetes during the post-pandemic period remain limited. This study assessed the VE against severe COVID-19 outcomes during both the pandemic and post-pandemic phases in children with and without diabetes mellitus (DM). A cohort study based on population data was carried out, including all patients under 18 years of age with symptomatic SARS-CoV-2 infection as registered in the Brazilian national surveillance systems from February 2020 to June 2025. The main outcomes were hospitalization due to COVID-19 and severe illness, which included admission to the intensive care unit (ICU), need for invasive ventilation, and death. Utilizing a propensity score-matched cohort, we estimated the VE and the number needed to vaccinate (NNV) for a booster dose against these outcomes by comparing vaccinated and unvaccinated individuals, employing conditional logistic regression adjusted for confounding variables. The cohort comprised 3,730,007 pediatric patients with COVID-19, of whom 7675 (0.2%) had DM. At baseline, children with DM exhibited a significantly higher prevalence of hospitalization (11.2% vs. 2.0%), severe COVID-19 (6.4% vs. 0.6%), and mortality (1.9% vs. 0.1%) than those without DM (all p < 0.001). During the pandemic period, the adjusted VE was consistently higher in children with DM. Against severe disease, the VE was 72.8% (95% CI: 12.3–93.2) in the DM cohort compared with 45.7% (28.1–59.0) in the non-DM cohort. This increased effectiveness corresponded to a more favorable NNV; the NNV to prevent one severe case was 24 (95% CI: 12–232) for children with DM versus 243 (168–440) for those without DM. In the post-pandemic period, the VE remained significantly higher in the DM cohort. Against severe disease, the VE was 76.2% (11.5–93.5) for children with DM and 52.9% (32.7–67.1) for those without. The NNV to prevent one severe case was consistently lower in the DM cohort (8 vs. 591). In conclusion, a complete vaccination regimen, including a booster dose, substantially mitigated severe COVID-19 outcomes in children with DM in the pandemic and post-pandemic periods.
- Open Access
- 11 October 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 198 (Pt A) , 111135
Enhanced LLM-supported instructions for medication use through retrieval-augmented generation
- 11 October 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 198 (Pt A) , 111135
Open AccessEnhanced LLM-supported instructions for medication use through retrieval-augmented generation
- Open Access
- 19 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Large Language Model–Generated Patient Instructions for Prescriptions in Primary Health Care: Preclinical Algorithm Validation (Preprint)
BACKGROUND The application of generative artificial intelligence to simplify medication use instructions has the potential to enhance people’s health by improving treatment adherence. OBJECTIVE We evaluated the performance of large language models (LLMs) in generating medication usage instructions to complement prescriptions in primary health care. METHODS This randomized, blinded experimental preclinical study used prescription-inducing scenarios, assigned to 62 health care professionals, to validate instructions generated by LLMs during electronic prescriptions. The instructions were generated by ChatGPT-4.0 (OpenAI), Llama3.1-8B (Meta), and Llama3.1-8B-RAG (Meta) using retrieval-augmented generation based on patient information leaflets. Performance metrics assessed adequacy, completeness, clarity, language simplification, usefulness, and errors in the generated instructions, with scores to analyze overall and individual metrics. RESULTS The 3 models yielded high overall scores for producing qualified instructions (ChatGPT-4.0: median 88.4, IQR 22.8; Llama3.1-8B: median 66.5, IQR 50.9; Llama3.1-8B-RAG: median 79.9, IQR 34.4; Kruskal-Wallis test P=.003). Llama3.1-8B-RAG received evaluations with similar overall scores to ChatGPT-4.0 (post hoc test, P=.05) and similar to Llama3.1-8B (post hoc test, P=.44). ChatGPT-4.0 outperformed Llama3.1-8B (Bonferroni test, P<.001). Regarding specific domains, Llama3.1-8B-RAG received scores equivalent to those of ChatGPT-4.0 for adequacy (mean 6.24, SD 2.3 vs mean 6.82, SD 2.1; post hoc test, P=.54); completeness (mean 5.94, SD 2.2 vs 6.55, SD 1.9; post hoc test P=.38), clarity (mean 5.77, SD 2.4 vs mean 6.68, SD 1.9; post hoc test P=.09), and usefulness (mean 5.42, SD 2.4 vs mean 5.96, SD 2.2; post hoc test P=.63). ChatGPT-4.0 received higher scores in the language simplification criterion than Llama3.1-8B-RAG (mean 7.05, SD 1.5 vs mean 5.44, SD 2.6; post hoc test P<.001). Interrater variability in assigning scores ranged from 4.2% (n=3) to 85.8% (n=6) among primary health care professionals. Instructions leading to incorrect use of the medication had similar frequency among the models(ChatGPT-4.0: n=15, 22.7%; Llama3.1-8B: n=19, 22.8%; Llama3.1-8B-RAG: n=19, 22.8%; chi-square test P=.71). The frequencies of hallucination were similar (ChatGPT-4.0: n=7, 10.6%; Llama3.1-8B: n=9, 13.6%; Llama3.1-8B-RAG: n=6, 9.1%; chi-square test P=.67). CONCLUSIONS The open-source LLM enhanced with external information presented similar performance to the closed-source model, except for ChatGPT4.0, which was superior in language simplification of messages. LLM generation demonstrated potential for instructing patients on medication use. Nonetheless, the introduction of this innovation into the electronic prescribing workflow demands prescriber validation for human oversight of the technology and requires a strategy for LLM performance governance. INTERNATIONAL REGISTERED REPORT RR2-10.12688/verixiv.1359.1
- 19 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessLarge Language Model–Generated Patient Instructions for Prescriptions in Primary Health Care: Preclinical Algorithm Validation (Preprint)
BACKGROUND The application of generative artificial intelligence to simplify medication use instructions has the potential to enhance people’s health by improving treatment adherence. OBJECTIVE We evaluated the performance of large language models (LLMs) in generating medication usage instructions to complement prescriptions in primary health care. METHODS This randomized, blinded experimental preclinical study used prescription-inducing scenarios, assigned to 62 health care professionals, to validate instructions generated by LLMs during electronic prescriptions. The instructions were generated by ChatGPT-4.0 (OpenAI), Llama3.1-8B (Meta), and Llama3.1-8B-RAG (Meta) using retrieval-augmented generation based on patient information leaflets. Performance metrics assessed adequacy, completeness, clarity, language simplification, usefulness, and errors in the generated instructions, with scores to analyze overall and individual metrics. RESULTS The 3 models yielded high overall scores for producing qualified instructions (ChatGPT-4.0: median 88.4, IQR 22.8; Llama3.1-8B: median 66.5, IQR 50.9; Llama3.1-8B-RAG: median 79.9, IQR 34.4; Kruskal-Wallis test P=.003). Llama3.1-8B-RAG received evaluations with similar overall scores to ChatGPT-4.0 (post hoc test, P=.05) and similar to Llama3.1-8B (post hoc test, P=.44). ChatGPT-4.0 outperformed Llama3.1-8B (Bonferroni test, P<.001). Regarding specific domains, Llama3.1-8B-RAG received scores equivalent to those of ChatGPT-4.0 for adequacy (mean 6.24, SD 2.3 vs mean 6.82, SD 2.1; post hoc test, P=.54); completeness (mean 5.94, SD 2.2 vs 6.55, SD 1.9; post hoc test P=.38), clarity (mean 5.77, SD 2.4 vs mean 6.68, SD 1.9; post hoc test P=.09), and usefulness (mean 5.42, SD 2.4 vs mean 5.96, SD 2.2; post hoc test P=.63). ChatGPT-4.0 received higher scores in the language simplification criterion than Llama3.1-8B-RAG (mean 7.05, SD 1.5 vs mean 5.44, SD 2.6; post hoc test P<.001). Interrater variability in assigning scores ranged from 4.2% (n=3) to 85.8% (n=6) among primary health care professionals. Instructions leading to incorrect use of the medication had similar frequency among the models(ChatGPT-4.0: n=15, 22.7%; Llama3.1-8B: n=19, 22.8%; Llama3.1-8B-RAG: n=19, 22.8%; chi-square test P=.71). The frequencies of hallucination were similar (ChatGPT-4.0: n=7, 10.6%; Llama3.1-8B: n=9, 13.6%; Llama3.1-8B-RAG: n=6, 9.1%; chi-square test P=.67). CONCLUSIONS The open-source LLM enhanced with external information presented similar performance to the closed-source model, except for ChatGPT4.0, which was superior in language simplification of messages. LLM generation demonstrated potential for instructing patients on medication use. Nonetheless, the introduction of this innovation into the electronic prescribing workflow demands prescriber validation for human oversight of the technology and requires a strategy for LLM performance governance. INTERNATIONAL REGISTERED REPORT RR2-10.12688/verixiv.1359.1
- Open Access
- 24 April 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (5) , 979
COVID-19 Vaccine Effectiveness and Risk Factors of Booster Failure in 480,000 Patients with Diabetes Mellitus: A Population-Based Cohort Study
To investigate the real-world effectiveness of COVID-19 vaccines in a large cohort of patients with diabetes mellitus (DM), we analyzed all >18-year-old patients with COVID-19 registered in a Brazilian nationwide surveillance database between February 2020 and February 2023. The primary outcome of interest was vaccine effectiveness against death, evaluated using multivariate logistic regression models. Among the 2,131,089 patients registered in the SIVEP-Gripe, 482,677 (22.6%) had DM. After adjusting for covariates, patients with DM had a higher risk of death than those without comorbidities (adjusted odds ratio [aOR] = 1.43, 95% CI, 1.39–1.47). For patients without comorbidities (72.7%, 95% CI, 70.5–74.7) and those with DM (73.4%, 95% CI, 68.2–76.7), vaccine effectiveness was similar after the booster dose. However, it was reduced in patients with DM associated with other comorbidities (60.5%; 95% CI, 57.5–63.2). The strongest factor associated with booster failure was the omicron variant (aOR = 27.8, 95% CI, 19.9–40.1). Our study revealed that COVID-19 vaccines provided robust protection against death in individuals with DM. However, our findings underscore the need to update vaccines and develop tailored strategies for individuals with diabetes, especially those with additional underlying conditions.
- 24 April 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (5) , 979
Open AccessCOVID-19 Vaccine Effectiveness and Risk Factors of Booster Failure in 480,000 Patients with Diabetes Mellitus: A Population-Based Cohort Study
To investigate the real-world effectiveness of COVID-19 vaccines in a large cohort of patients with diabetes mellitus (DM), we analyzed all >18-year-old patients with COVID-19 registered in a Brazilian nationwide surveillance database between February 2020 and February 2023. The primary outcome of interest was vaccine effectiveness against death, evaluated using multivariate logistic regression models. Among the 2,131,089 patients registered in the SIVEP-Gripe, 482,677 (22.6%) had DM. After adjusting for covariates, patients with DM had a higher risk of death than those without comorbidities (adjusted odds ratio [aOR] = 1.43, 95% CI, 1.39–1.47). For patients without comorbidities (72.7%, 95% CI, 70.5–74.7) and those with DM (73.4%, 95% CI, 68.2–76.7), vaccine effectiveness was similar after the booster dose. However, it was reduced in patients with DM associated with other comorbidities (60.5%; 95% CI, 57.5–63.2). The strongest factor associated with booster failure was the omicron variant (aOR = 27.8, 95% CI, 19.9–40.1). Our study revealed that COVID-19 vaccines provided robust protection against death in individuals with DM. However, our findings underscore the need to update vaccines and develop tailored strategies for individuals with diabetes, especially those with additional underlying conditions.
- Open Access
- 6 June 2023
- Published by Springer Nature in BMC Medicine
- Vol. 21 (1) , 1-2
Correction: Development and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients
- 6 June 2023
- Published by Springer Nature in BMC Medicine
- Vol. 21 (1) , 1-2
Open AccessCorrection: Development and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients
- Open Access
- 2 September 2022
- Published by Springer Nature in BMC Medicine
- Vol. 20 (1) , 1-13
Development and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients
Background: Acute kidney injury (AKI) is frequently associated with COVID-19, and the need for kidney replacement therapy (KRT) is considered an indicator of disease severity. This study aimed to develop a prognostic score for predicting the need for KRT in hospitalised COVID-19 patients, and to assess the incidence of AKI and KRT requirement. Methods: This study is part of a multicentre cohort, the Brazilian COVID-19 Registry. A total of 5212 adult COVID-19 patients were included between March/2020 and September/2020. Variable selection was performed using generalised additive models (GAM), and least absolute shrinkage and selection operator (LASSO) regression was used for score derivation. Accuracy was assessed using the area under the receiver operating characteristic curve (AUC-ROC). Results: The median age of the model-derivation cohort was 59 (IQR 47–70) years, 54.5% were men, 34.3% required ICU admission, 20.9% evolved with AKI, 9.3% required KRT, and 15.1% died during hospitalisation. The temporal validation cohort had similar age, sex, ICU admission, AKI, required KRT distribution and in-hospital mortality. The geographic validation cohort had similar age and sex; however, this cohort had higher rates of ICU admission, AKI, need for KRT and in-hospital mortality. Four predictors of the need for KRT were identified using GAM: need for mechanical ventilation, male sex, higher creatinine at hospital presentation and diabetes. The MMCD score had excellent discrimination in derivation (AUROC 0.929, 95% CI 0.918–0.939) and validation (temporal AUROC 0.927, 95% CI 0.911–0.941; geographic AUROC 0.819, 95% CI 0.792–0.845) cohorts and good overall performance (Brier score: 0.057, 0.056 and 0.122, respectively). The score is implemented in a freely available online risk calculator (https://www.mmcdscore.com/). Conclusions: The use of the MMCD score to predict the need for KRT may assist healthcare workers in identifying hospitalised COVID-19 patients who may require more intensive monitoring, and can be useful for resource allocation.
- 2 September 2022
- Published by Springer Nature in BMC Medicine
- Vol. 20 (1) , 1-13
Open AccessDevelopment and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients
Background: Acute kidney injury (AKI) is frequently associated with COVID-19, and the need for kidney replacement therapy (KRT) is considered an indicator of disease severity. This study aimed to develop a prognostic score for predicting the need for KRT in hospitalised COVID-19 patients, and to assess the incidence of AKI and KRT requirement. Methods: This study is part of a multicentre cohort, the Brazilian COVID-19 Registry. A total of 5212 adult COVID-19 patients were included between March/2020 and September/2020. Variable selection was performed using generalised additive models (GAM), and least absolute shrinkage and selection operator (LASSO) regression was used for score derivation. Accuracy was assessed using the area under the receiver operating characteristic curve (AUC-ROC). Results: The median age of the model-derivation cohort was 59 (IQR 47–70) years, 54.5% were men, 34.3% required ICU admission, 20.9% evolved with AKI, 9.3% required KRT, and 15.1% died during hospitalisation. The temporal validation cohort had similar age, sex, ICU admission, AKI, required KRT distribution and in-hospital mortality. The geographic validation cohort had similar age and sex; however, this cohort had higher rates of ICU admission, AKI, need for KRT and in-hospital mortality. Four predictors of the need for KRT were identified using GAM: need for mechanical ventilation, male sex, higher creatinine at hospital presentation and diabetes. The MMCD score had excellent discrimination in derivation (AUROC 0.929, 95% CI 0.918–0.939) and validation (temporal AUROC 0.927, 95% CI 0.911–0.941; geographic AUROC 0.819, 95% CI 0.792–0.845) cohorts and good overall performance (Brier score: 0.057, 0.056 and 0.122, respectively). The score is implemented in a freely available online risk calculator (https://www.mmcdscore.com/). Conclusions: The use of the MMCD score to predict the need for KRT may assist healthcare workers in identifying hospitalised COVID-19 patients who may require more intensive monitoring, and can be useful for resource allocation.
- Open Access
Development and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients
Background: Acute kidney injury (AKI) is frequently associated with COVID-19 and the need for kidney replacement therapy (KRT) is considered an indicator of disease severity. This study aimed to develop a prognostic score for predicting the need for KRT in hospitalized COVID-19 patients. Methods: This study is part of the multicentre cohort, the Brazilian COVID-19 Registry. A total of 5,212 adult COVID-19 patients were included between March/2020 and September/2020. We evaluated four categories of predictor variables: (1) demographic data; (2) comorbidities and conditions at admission; (3) laboratory exams within 24 h; and (4) the need for mechanical ventilation at any time during hospitalization. Variable selection was performed using generalized additive models (GAM) and least absolute shrinkage and selection operator (LASSO) regression was used for score derivation. The accuracy was assessed using the area under the receiver operating characteristic curve (AUC-ROC). Risk groups were proposed based on predicted probabilities: non-high (up to 14.9%), high (15.0 – 49.9%), and very high risk (≥ 50.0%). Results: The median age of the model-derivation cohort was 59 (IQR 47-70) years, 54.5% were men, 34.3% required ICU admission, 20.9% evolved with AKI, 9.3% required KRT, and 15.1% died during hospitalization. The validation cohort had similar age, sex, ICU admission, AKI, required KRT distribution and in-hospital mortality. Thirty-two variables were tested and four important predictors of the need for KRT during hospitalization were identified using GAM: need for mechanical ventilation, male gender, higher creatinine at admission, and diabetes. The MMCD score had excellent discrimination in derivation (AUROC = 0.929; 95% CI 0.918–0.939) and validation (AUROC = 0.927; 95% CI 0.911–0.941) cohorts an good overall performance in both cohorts (Brier score: 0.057 and 0.056, respectively). The score is implemented in a freely available online risk calculator ( https://www.mmcdscore.com/ ). Conclusion: The use of the MMCD score to predict the need for KRT may assist healthcare workers in identifying hospitalized COVID-19 patients who may require more intensive monitoring, and can be useful for resource allocation.
Open AccessDevelopment and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients
Background: Acute kidney injury (AKI) is frequently associated with COVID-19 and the need for kidney replacement therapy (KRT) is considered an indicator of disease severity. This study aimed to develop a prognostic score for predicting the need for KRT in hospitalized COVID-19 patients. Methods: This study is part of the multicentre cohort, the Brazilian COVID-19 Registry. A total of 5,212 adult COVID-19 patients were included between March/2020 and September/2020. We evaluated four categories of predictor variables: (1) demographic data; (2) comorbidities and conditions at admission; (3) laboratory exams within 24 h; and (4) the need for mechanical ventilation at any time during hospitalization. Variable selection was performed using generalized additive models (GAM) and least absolute shrinkage and selection operator (LASSO) regression was used for score derivation. The accuracy was assessed using the area under the receiver operating characteristic curve (AUC-ROC). Risk groups were proposed based on predicted probabilities: non-high (up to 14.9%), high (15.0 – 49.9%), and very high risk (≥ 50.0%). Results: The median age of the model-derivation cohort was 59 (IQR 47-70) years, 54.5% were men, 34.3% required ICU admission, 20.9% evolved with AKI, 9.3% required KRT, and 15.1% died during hospitalization. The validation cohort had similar age, sex, ICU admission, AKI, required KRT distribution and in-hospital mortality. Thirty-two variables were tested and four important predictors of the need for KRT during hospitalization were identified using GAM: need for mechanical ventilation, male gender, higher creatinine at admission, and diabetes. The MMCD score had excellent discrimination in derivation (AUROC = 0.929; 95% CI 0.918–0.939) and validation (AUROC = 0.927; 95% CI 0.911–0.941) cohorts an good overall performance in both cohorts (Brier score: 0.057 and 0.056, respectively). The score is implemented in a freely available online risk calculator ( https://www.mmcdscore.com/ ). Conclusion: The use of the MMCD score to predict the need for KRT may assist healthcare workers in identifying hospitalized COVID-19 patients who may require more intensive monitoring, and can be useful for resource allocation.